Carl Zeiss Meditec reorganises management of its strategic business units

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Dr. Ludwin Monz takes over Ophthalmic Systems business unit - Thomas
Simmerer new Head of Neuro/ENT Surgery - James L. Taylor to leave
company and assume a consulting role for CZM

(Jena, 15 September 2008) Medical technology supplier Carl Zeiss
Meditec AG, listed in the TecDAX at the German Stock Exchange (ISIN
DE0005313704), is expanding the management of its strategic business
units. In doing so the company is creating a further important
prerequisite for accelerating its expansion course as announced.
James L. Taylor, hitherto Head of the SBU Ophthalmic Systems, will be
leaving the company for personal reasons on 30 September 2008. He
will continue to be available to Carl Zeiss Meditec as a consultant
in strategic, organisational and clinical application-related
matters. The regional focus will be placed on the US market. With
effect from 1 October 2008, Board Member Dr. Ludwig Monz has been
appointed new Head of the SBU Ophthalmic Systems. He was previously
responsible for the SBU Neuro/ENT Surgery, which he successfully set
on a profitable expansion course. In his new position Dr. Ludwig Monz
intends to further expand the innovative power of Ophthalmic Systems,
which includes diagnostic and therapeutic systems for ophthalmology,
thereby securing the long-term success of this business unit.
Dr. Ludwig Monz is concurrently handing over the helm of Neuro/ENT
Surgery to Thomas Simmerer. Thomas Simmerer joined Carl Zeiss Meditec
on 1 September 2008. He has gained broad experience in medical
technology, of late at Dräger Medical AG & Co. KG, where he held
various managerial positions, most recently serving as head of a
business unit.
The management of the SBU Surgical Ophthalmology is to remain in the
hands of Dr. Christian Müller. He has been responsible for this unit
since
2006. During this time he has actively and successfully promoted its
expansion and implemented the integration of Acri.Tec.
"Mr Taylor has been instrumental in making Carl Zeiss Meditec one of
the leading companies in the field of ophthalmology in the past few
years. My sincere thanks are due to him for his effort and
dedication. I am pleased that Mr Taylor will continue to support us
in the role of independent consultant and that we will be able to
draw on his experience in future. Furthermore, I am convinced that we
are ideally set with our current team to accelerate the proposed
realisation of growth potential of Carl Zeiss Meditec," says Dr.
Michael Kaschke, President and CEO of Carl Zeiss Meditec.
Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's
leading medical technology companies. This market position is based
on over 160 years of experience in optical innovation.
The company has two primary areas of activity: In the field of
ophthalmology Carl Zeiss Meditec offers integrated solutions for
treating the four main eye diseases: vision defects (refraction),
cataracts, glaucoma and retinal disorders. The company's system
solutions are employed in all phases of the disease management, from
diagnosis to treatment and follow-up. Carl Zeiss Meditec has always
applied its technological expertise to product innovations. These
innovations range from basic systems such as slit lamps and fundus
cameras to standard setting diagnostic systems such as the Humphrey®
Field Analyser, the Cirrus HD-OCT(TM) and the IOLMaster®, through to
the surgical microscopes and innovative treatment systems in
refractive laser surgery. The product portfolio in ophthalmic surgery
is rounded off by intraocular lenses and consumables.
In the field of neuro and ENT surgery, Carl Zeiss Meditec is the
world's leading provider of surgical microscopes and microsurgical
visualisation solutions for a very broad range of applications, such
as tumor and vascular surgery in the head region and/or spinal
surgery. The most recent example of the innovative performance in the
area of microsurgery is the OPMI Pentero® visualisation system, which
allows efficient and ergonomic patient treatment. Carl Zeiss Meditec
will systematically expand its product range in this area and become
a solution provider in neuro and ENT surgery as well.
Carl Zeiss Meditec's medical technology portfolio is rounded off by
visualisation systems for doctors in private practice and promising
future technologies such as intraoperative radiation therapy, which
allows the targeted treatment of breast cancer and brain cancer
directly during surgery.
Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in
Germany (Carl Zeiss Surgical GmbH, Carl Zeiss Meditec
Vertriebsgesellschaft mbH, Acri.Tec AG and Carl Zeiss Medical
Software GmbH), the USA (Carl Zeiss Meditec, Inc., Dublin), in Japan
(Carl Zeiss Meditec Co., Ltd., Tokyo), Spain (Carl Zeiss Meditec
Iberia S.A., Madrid) and France (Carl Zeiss Meditec S.A.S., La
Rochelle, and Carl Zeiss Meditec France SAS, Le Pecq).
Thirty-five percent of Carl Zeiss Meditec shares are in free float.
The remaining 65 percent are held by Carl Zeiss, one of the world's
leading international groups engaged in the optical and
opto-electronics industry.

Contact
Eva Sesselmann
Director Corporate Communications
Goeschwitzer Straße 51-52
07745 Jena, Germany
Telephone: +49 (0) 36 41 - 2 20 - 331 Telefax: +49 (0) 36 41 - 2 20 -
112
E-Mail: e.sesselmann@meditec.zeiss.com Web:
http://www.meditec.zeiss.com

--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN:
531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share,
TecDAX;
Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Stuttgart,
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse, Geregelter Markt in
Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2008. All rights reserved.